FATE Stock Overview
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
My Notes
NewNotes are coming soon
Fate Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$5.96 |
52 Week High | US$43.12 |
52 Week Low | US$4.02 |
Beta | 1.62 |
1 Month Change | -40.93% |
3 Month Change | -69.36% |
1 Year Change | -84.95% |
3 Year Change | -77.58% |
5 Year Change | -25.87% |
Change since IPO | -9.97% |
Recent News & Updates
Recent updates
We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully
Jan 10Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation
Sep 22We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely
Jun 02We're Not Very Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate
Feb 01Fate Therapeutics (NASDAQ:FATE) Is In A Good Position To Deliver On Growth Plans
Oct 16Companies Like Fate Therapeutics (NASDAQ:FATE) Can Afford To Invest In Growth
Jul 18This Is Why Fate Therapeutics, Inc.'s (NASDAQ:FATE) CEO Compensation Looks Appropriate
May 26Companies Like Fate Therapeutics (NASDAQ:FATE) Can Afford To Invest In Growth
Apr 13Fate Therapeutics, Inc.'s (NASDAQ:FATE) Intrinsic Value Is Potentially 41% Above Its Share Price
Feb 19J. Wolchko Is The Founder of Fate Therapeutics, Inc. (NASDAQ:FATE) And They Just Sold 28% Of Their Shares
Jan 15Companies Like Fate Therapeutics (NASDAQ:FATE) Can Afford To Invest In Growth
Jan 01Shareholder Returns
FATE | US Biotechs | US Market | |
---|---|---|---|
7D | 10.4% | -0.2% | 1.7% |
1Y | -84.9% | 3.9% | -12.5% |
Return vs Industry: FATE underperformed the US Biotechs industry which returned 1.2% over the past year.
Return vs Market: FATE underperformed the US Market which returned -13.6% over the past year.
Price Volatility
FATE volatility | |
---|---|
FATE Average Weekly Movement | 21.7% |
Biotechs Industry Average Movement | 12.3% |
Market Average Movement | 6.9% |
10% most volatile stocks in US Market | 17.5% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: FATE is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 22% a week.
Volatility Over Time: FATE's weekly volatility has increased from 15% to 22% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 545 | J. Wolchko | https://www.fatetherapeutics.com |
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd.
Fate Therapeutics, Inc. Fundamentals Summary
FATE fundamental statistics | |
---|---|
Market Cap | US$579.14m |
Earnings (TTM) | -US$293.98m |
Revenue (TTM) | US$69.01m |
8.4x
P/S Ratio-2.0x
P/E RatioIs FATE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
FATE income statement (TTM) | |
---|---|
Revenue | US$69.01m |
Cost of Revenue | US$12.99m |
Gross Profit | US$56.03m |
Other Expenses | US$350.01m |
Earnings | -US$293.98m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -3.03 |
Gross Margin | 81.18% |
Net Profit Margin | -425.98% |
Debt/Equity Ratio | 0% |
How did FATE perform over the long term?
See historical performance and comparison